Logo-hpp
2022: Two-year Impact Factor: 4.4
Scopus Journal Metrics
CiteScore (2022): 5.3
SNIP(2022):1.389
SJR(2022): 0.78
Platinum
Open Access

Health Promot Perspect. 2020;10(1): 38-42. doi: 10.15171/hpp.2020.07
PMID: 32104655        PMCID: PMC7036205

Original Article

Prevalence of hepatitis D virus among HBsAg-positive individuals,2015-2016: Azar cohort study

Ali Asghar Pouri 1 ORCID, Morteza Ghojazadeh 1 ORCID, Babak Baiaz 2, Fatemeh Soghra Hamzavi 2, Behrouz Pourasghari 2, Mohammad Hossein Somi 1 * ORCID

Cited by CrossRef: 5


1- Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. Journal of Hepatology. 2021;74(5):1200 [Crossref]
2- Lazarus J, Al‐Rifai A, Sanai F, Alghamdi A, Sharara A, Saad M, van Selm L, Alqahtani S. Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: A scoping review. Liver International. 2023;43(S1):116 [Crossref]
3- Isaeva O, Kyuregyan K, Karlsen A, Kuzmin O, Potemkin I, Kichatova V, Asadi Mobarkhan F, Mullin E, Kozhanova T, Manuylov V, Pochtovyy A, Gushchin V, Saryglar A, Ilchenko L, Mikhailov M. Silent HDV epidemics culminates in high levels of liver cirrhosis in endemic region despite 20 years of HBV vaccination. Journal of Viral Hepatitis. 2023;30(3):182 [Crossref]
4- Post Z, Reau N. What Is the Real Epidemiology of Hepatitis D Virus and Why so Many Mixed Messages?. Clinics in Liver Disease. 2023;27(4):973 [Crossref]
5- Abdul Majeed N, Zehnder B, Koh C, Heller T, Urban S. Hepatitis delta: Epidemiology to recent advances in therapeutic agents. 2023;78(4):1306 [Crossref]

Indexing and Abstracting

2-year Impact Factor: 4.4

  


     Linked in Profile

   Academia Profile

Officially associated with The Iranian Health Education & Promotion Association  

Publication Advantages

Free of charge publication

Open access 

Fast and constructive peer review

Easy and fast online submission